{‘She has no expertise’: this US healthcare field prepares for Dr. Høeg's appointment at the Food and Drug Administration.

As the US undertakes unprecedented revisions to its immunization guidelines, one figure has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who initially gained attention by casting doubt on COVID-19 shots throughout the pandemic and has concentrated on potential fatalities after Covid vaccination in her recent position at the FDA.

Planned Shifts to Childhood Immunization Schedule

Public health authorities planned to reveal sweeping revisions to the childhood immunization program recently, synchronizing the US with the Danish immunization schedule, it is understood – a substantial departure that would put the US out of alignment with a large portion of the global community with no evidence for public health gain. The announcement has been pushed back until the next year.

In place of the director of the vaccine center, Tracy Beth Høeg is scheduled to address the audience at the event. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the center this calendar year.

A New Direction at the Agency

Høeg's temporary position might represent a strengthened alliance between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it points to a renewed priority upon rolling back long-standing immunizations at the FDA.

The new acting director has repeatedly called for discontinuing certain pediatric vaccine recommendations in the US to become more similar to Denmark, a country with nationalized medicine and a citizenry approximately the size of Wisconsin’s.

To date public appearances, she has kept her attention on vaccination policy – usually the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Doubts Over Qualifications

The appointee has no apparent track record in drug development, approval processes or administrative roles, which has been standard for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the agency head and CBER since earlier this year.

“She appears not to have the requisite experience” for running the CDER, stated a neurologist and psychiatrist. “She lacks experience running a clinical trial. She is not versed in running a sizeable institution. She is not an expert in pharmaceutical oversight.”

Past commissioners of CBER would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, noted a former acting FDA commissioner. “Objectively, she doesn’t have the kind of background that prior appointees who ran the center have had.”

This division has an enormous range of responsibilities at the agency, she stated.

“Everybody just zeroes in on the innovative therapies, but the off-patent medication office authorizes numerous off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and so forth, and every single one must be supervised,” Dr. Woodcock said. “The responsibility you neglect, that’s the thing that I always told people is going to cause problems.”

Additionally, a major leadership component to the position, which oversees in excess of 5,000 personnel. “It’s a massive management job, if you execute it properly,” the former official said.

Agency Reaction and Controversial Programs

In response to inquiries about Dr. Høeg's credentials and whether this assignment represents greater collaboration among FDA leaders on immunizations, a spokesperson responded that the “inquiries rely on inaccurate premises”.

“This background is consistent with the duties of her job,” the representative said, citing the time Dr. Høeg spent advising the agency head on “medication safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the agency head's new priority voucher program, a disputed one-day therapy clearance system that apparently troubled her preceding directors. “By what process are these drugs being picked for this voucher program? Who makes the decisions?” Dr. Howard asked. “There is a lot of lack of transparency going on at the regulatory body right now.”

Broadly speaking, he remarked, “the agency seems to be moving towards less stringent oversight of all drugs, aside from shots.”

Public Track Record on Vaccines

Regarding immunizations, Høeg has a more established, if troubling, past, some experts have noted. She published a research paper using unconfirmed volunteer-provided data to estimate the frequency of myocarditis following COVID-19 immunization. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccines are pose a greater threat than they are.

Part of her “desired changes” for the incoming government featured changing guidelines for novel immunizations and discontinuing “unnecessary” vaccines, she said following the vote on a online show. At the agency, Høeg has reportedly suggested excluding adolescent males from obtaining COVID-19 vaccinations.

“She’s an all-around dogmatist who begins with her conclusions and works backwards to retrofit the evidence in a very disingenuous, fraudulent manner,” Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg joined other dissenters, {like|